| | | | 6 | | | | | 21 | | | | | 2020 2 | | | 21 | 4 | 3 8 | Ⅲ 1mRNA | | | | 3.5 | 90 | 73 | | | | | 90 | 2 | | 7 | | | | 3.5 80 40 | 2020 10 | COVAX 1000 | | | | | | | | 5 16 | 1325 | 14 65.3% | 87% | 90.3% 86% | | | | 7 | 11.86 /10 83% | 17% 2019 | | | 70% | | 300 200 | | | 3 24 | 5 | 7 | | | | | | | | | | | | | | Ⅲ | | | | | | | | 18 | 100 | 3 17 | | | | Ⅰ/Ⅱ | GMP | Ⅲ | | 6 6 | | | |